Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy (UC-MSCs)

Clinical Research of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) in the Treatment of Diabetic Nephropathy

Diabetic nephropathy (DN) is one of the most serious complications of diabetes and the leading cause of end-stage chronic kidney disease. DN is a refractory disease with low awareness, high incidence, and high disability. The incidence of DN can reach 30 to 40% after 20 years of diabetes, of which 5~10% of patients will progress to end-stage renal disease, and epidemiological surveys predict that by 2030, DN will become the seventh leading cause of death in the world. Currently, there are no effective drugs for treating DN. This clinical trial is to inspect the safety and efficiency of human umbilical cord mesenchymal stem cells (UC-MSCs) therapy for patients with DN.

Study Overview

• Status: Unknown
• Conditions: Diabetic Nephropathy
• Intervention / Treatment: Drug: UC-MSCs; Drug: Placebo

Detailed Description

Diabetic nephropathy (DN) is one of the most important microvascular complications of diabetes. It is a persistent and refractory disease. There is currently a lack of effective clinical treatments for DN. The basic pathological processes of DN are renal tissue cell damage, apoptosis and continuous increase of inflammatory cytokines induced by early high glucose, which gradually leads to glomerular sclerosis and renal fibrosis.

Human umbilical cord mesenchymal stem cells (UC-MSCs), as the "youngest" adult stem cells, have powerful anti-inflammatory functions, stronger differentiation potential, and good safety. They are ideal seed cells for the treatment of DN. At present, studies on a variety of animal models of DN have shown that mesenchymal stem cell transplantation can delay the progression of DN and have a certain repair effect on damaged kidney tissue and renal function. Our previous preclinical study showed that UC-MSCs effectively improved the renal function, inhibited inflammation and fibrosis, and prevented its progression in a rat model of diabetes-induced chronic renal injury. Some autologous or allogeneic mesenchymal stem cells have been carried out abroad treatment of chronic kidney disease caused by various reasons, including clinical trials of DN, phase I/II test results did not show obvious adverse reactions related to stem cell therapy, and can improve the patient's renal function and quality of life to a certain extent.

The purpose of this study is to investigate efficiency and safety of UC-MSCs in treating DN patients. This trial will recruit 38 patients. 19 patients received the treatment of conventional treatment + equal volume normal saline containing 1% human albumin (placebo group) were used as control group; conventional treatment + 1*10E6 UC-MSCs/kg body weight (experimental group) for intravenous infusion (once a week, 3 times in total) to treat 19 patients with DN (by unified standard inclusion), and subjects will be followed a total of 48 weeks from time of initial cell treatment.

• Study Type: Interventional
• Enrollment (Anticipated): 38
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Huiming Wang, MD; Phone Number: 18971563100; Email: rm000301@whu.edu.cn
• Study Contact Backup: Name: Yujuan Wang, MD; Phone Number: 15926267337; Email: 541785638@qq.com

Study Locations

• China
  • Hubei China
    • Wuhan, Hubei China, China, 430075
      • Recruiting
      • Renmin Hospital of Wuhan University
      • Contact: Yujuan Wang, MD; Phone Number: 15926267337; Email: 541785638@qq.com
      • Principal Investigator: Huiming Wang, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Type 2 diabetes mellitus, course 5-15 years;
2. Age 30-65 years old, no gender limit;
3. Accompanied by proteinuria, urine albumin/creatinine ratio (UACR)>300mg/g or 24h urine protein quantitative>0.5g/24h;
4. eGFR is between 30-60 ml/min/1.732 m2;
5. Take RASI-based antihypertensive drugs to control blood pressure and blood pressure meets the following standards: systolic blood pressure <150mmHg, and diastolic blood pressure <100mmHg;
6. Blood lipids and blood uric acid are controlled at appropriate levels;
7. The pathological diagnosis of kidney biopsy is diabetic nephropathy;
8. Patients who have good compliance, signed informed consent, and can complete the entire trial treatment and follow-up plan according to the research plan；
9. No exclusion criteria are positive.

Exclusion Criteria:

1. Have a history of primary glomerulonephritis, lupus nephritis, ANCA-related small vasculitis, renal damage, allergic purpura nephritis, hepatitis B-related nephritis;
2. Poor blood glucose control: HbA1c ≥9% of patients or 2h postprandial blood glucose> 22mmol/L;
3. Active liver disease or liver function test results are obviously abnormal (ALT or AST ≥ 2 times the upper limit of normal);
4. White blood cell count<3.0×10E9/L, hemoglobin<80 g/L, platelet count<100×10E9/L or suffering from other blood system diseases (severe anemia, idiopathic thrombocytopenic purpura, splenomegaly, Patients with coagulopathy, etc.);
5. Severe and unstable cardiovascular and cerebrovascular diseases (unstable angina pectoris, coronary artery disease, cerebrovascular disease, transient ischemic attack, congestive heart failure, etc.), acute and uncontrollable disease, still unable to effectively control severe hypertension (blood pressure> 160/100 mmHg) after treatment or organ transplant patients;
6. The dose of antihypertensive drugs and/or hypoglycemic drugs used in the past 3 months has increased significantly than before;
7. Uncontrolled infection;
8. Suffer from tumor or abnormal level of tumor markers;
9. Suffer from blood-borne diseases (for example, HIV, syphilis, hepatitis B and hepatitis C);
10. Possibility of pregnancy, preparation for pregnancy or breastfeeding;
11. Receive immunosuppressive treatment;
12. Have a history of allergies, especially those who are allergic to human albumin;
13. Suffer from mental illness, which will affect their voluntariness, decision-making ability and communication ability;
14. A history of alcohol abuse or a known history of drug abuse in the last 2 years;
15. Participate in another clinical trial within the last 3 months;
16. Poor compliance, unable to complete the entire study；
17. The researcher diagnosed that the patient is not suitable for this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: UC-MSCs treatment group; Conventional treatment plus UC-MSCs: Participants will receive conventional treatment plus 3 times of UC-MSCs (1*10E6 UC-MSCs/kg body weight/100mL intravenously at week 1, week 2，week3).	Drug: UC-MSCs; 3 times of UC-MSCs (1*10E6 UC-MSCs/kg body weight/100mL saline containing 1% human albumin intravenously at week 1,week 2, week 3).; Other Names: UC-MSCs treatment group
PLACEBO_COMPARATOR: Placebo control group; Conventional treatment plus Placebo: Without UC-MSCs therapy but conventional treatment should be received. Participants will receive conventional treatment plus 3 times of Placebo intravenously at week 1, week 2，week3.	Drug: Placebo; 3 times of cell-free stem cell suspension (saline containing 1% human albumin/100mL intravenously at week 1, week 2, week 3).; Other Names: Placebo control group

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events	The number of Adverse Events associated with UC-MSCs intervention per treatment arm	From Baseline (0 W) to 48 weeks after treatment
Adverse Events	The percentage of Adverse Events associated with UC-MSCs intervention per treatment arm	From Baseline (0 W) to 48 weeks after treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Kidney function	Change in estimated glomerular filtration rate (eGFR) from baseline.	From Baseline (0 W) to 48 weeks after treatment
Kidney function	Change in 24-hour urinary protein quantification from baseline.	From Baseline (0 W) to 48 weeks after treatment
Kidney function	Change in urinary albumin/creatinine ratio from baseline	From Baseline (0 W) to 48 weeks after treatment
Kidney function	The proportion of subjects in both groups who progressed to end-stage renal disease (ESRD) or doubled their serum creatinine.	From Baseline (0 W) to 48 weeks after treatment
SF-36 (The MOS item short from health survey)	The MOS item short from health survey, SF-36 and changes per visit. As a concise health questionnaire, SF-36 comprehensively summarizes the quality of life of the surveyed from 8 aspects: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. Higher scores mean a better outcome.	From Baseline (0 W) to 48 weeks after treatment
Change in HbA1c	Change in Glycosylated Hemoglobin (HbA1c) from baseline.	From Baseline (0 W) to 48 weeks after treatment

Collaborators and Investigators

• Sponsor: Renmin Hospital of Wuhan University
• Collaborators: Wuhan Hamilton Biotechnology Co., Ltd

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): September 25, 2020
• Primary Completion (ANTICIPATED): September 25, 2021
• Study Completion (ANTICIPATED): December 31, 2021

Study Registration Dates

• First Submitted: September 16, 2020
• First Submitted That Met QC Criteria: September 22, 2020
• First Posted (ACTUAL): September 24, 2020

Study Record Updates

• Last Update Posted (ACTUAL): September 24, 2020
• Last Update Submitted That Met QC Criteria: September 22, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Keywords: Cell Therapy; Safety; Diabetic Nephropathy; Efficiency; UC-MSCs
• Additional Relevant MeSH Terms: Urologic Diseases; Endocrine System Diseases; Diabetes Complications; Diabetes Mellitus; Kidney Diseases; Diabetic Nephropathies
• Other Study ID Numbers: 20200915HMD

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No